A new study published in JNCCN finds that a cost-effective education program targeting survivors and their doctors can increase screening rates for skin cancer. The study showed that practical solutions can close the gap between elevated risks and low screening rates, especially after transitioning out of specialty care.
City of Hope's IMMUNO-BIOMAP trial aims to map how tumors change as they resist immunotherapy, focusing on non-small cell lung cancer. The six-year trial will use predictive models to identify groups of patients who respond well to personalized treatments.
City of Hope launches nationwide platform to share messages of encouragement with cancer survivors and their loved ones, offering tailored survivorship care and coordination between specialists and primary care physicians. The organization's data-driven model integrates supportive care from diagnosis through decades of follow-up.
City of Hope researchers showcase new findings on tailored cancer treatments based on tumor biology and patient-specific factors. Microbiome insights suggest a potential biomarker for guiding treatment selection in kidney cancer, while bispecific antibody combination improves outcomes for patients with lymphoma.
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
Researchers developed a microfluidic platform that squeezes individual breast epithelial cells to measure their mechanical age, revealing an unexpected insight: older cells are stiffer and at higher risk of cancer. The AI-powered platform provides a non-genetic test for women with unknown genetic risks.
Researchers at City of Hope present findings on early-onset colorectal cancer, highlighting the role of gut microbiome differences and a new molecular pathway in immune resistance. The study uses AI tools to analyze complex relationships between data types, shedding light on potential strategies for earlier detection and treatment.
A new study reveals that excess weight can physically enlarge organs, creating more opportunities for cancer to take hold. The study found that organs grew larger as body weight increased, with the liver growing by 12%, kidneys by 9%, and pancreas by 7% for every 5-point increase in BMI.
Researchers found that specific gut bacteria can sense diet and translate information into signals that tell fat cells to burn energy. A low-protein diet activated precise gut microbes that promote beige fat production, leading to improved glucose control and lower cholesterol levels.
Researchers at City of Hope have made significant breakthroughs in cancer treatment, immune system regulation and early disease detection. A study found that subtle RNA changes can shape cancer behavior, opening new avenues for precision oncology. In contrast, combining immunotherapy with chemoradiation did not improve survival rates f...
A phase 2 clinical trial is comparing three strategies to protect heart health in prostate cancer patients undergoing hormone therapy. The study will assess the impact of intermittent fasting, GLP-1 medication, and nutritional counseling on cardiovascular and metabolic risks associated with androgen deprivation therapy.
The American Cancer Society's new 'Cancer Statistics, 2026' report reveals a historic milestone: US cancer survivorship has reached a record 70%, driven by major gains in cancers once considered difficult to treat. However, the report also highlights persistent disparities, concerning increases in cancer among women and younger adults.
The collaboration aims to address bottlenecks in solid tumor manufacturing and accelerate advancement into clinical trials. City of Hope's investigational gene-modified CAR T cell therapy targeting glioblastoma will be evaluated using Cellares' automated manufacturing platform and quality control system.
A landmark study published in Nature Metabolism reveals how citrin deficiency, a rare genetic disorder, triggers fat buildup in the liver despite being lean. The research also discovers a hormone that reduces cravings for sweets and alcohol, providing new therapeutic targets for MASLD and fatty liver disease.
Researchers from City of Hope presented results on novel cellular and immunotherapies, treatment strategies for hard-to-treat blood cancers, and a first-in-human trial for GVHD. The studies showed promising outcomes, including higher event-free survival rates and fewer side effects.
City of Hope researchers have made significant breakthroughs in cancer treatment, including a long-term survival boost for advanced prostate cancer patients, targeting IL-18 to improve immune function, and identifying a new target for pancreatic cancer therapy. These discoveries offer promising strategies for improving patient outcomes...
City of Hope experts will highlight advances in blood cancer research, cellular therapies, and precision medicine at the 2025 American Society of Hematology Annual Meeting and Exposition. The meeting will feature over 105 sessions covering topics such as CAR T cell therapy, transplant innovations, and precision medicine.
Dr. Lovly brings nearly two decades of experience in clinical care, research and academic leadership to her new role, shaping the modern landscape of lung cancer care. Her expertise in precision medicine will be instrumental in accelerating progress for patients with lung cancer across the country.
Researchers at City of Hope have identified a potential strategy to overcome treatment resistance in acute myeloid leukemia and uncovered racial disparities in triple-negative breast cancer. By targeting the ALKBH1 protein, which enhances energy production in cancer cells, scientists found that blocking this protein could make CAR T th...
Researchers at City of Hope have identified a gene called SMOC1 that converts insulin-producing cells into those that increase blood sugar, shedding light on the progression of type 2 diabetes. This discovery offers new therapeutic targets and potential treatments for T2D.
Researchers at City of Hope have made significant breakthroughs in understanding genetic mutations, identifying a potential new treatment for acute myeloid leukemia, and uncovering the role of DNA methylation in preventing tangle-prone sequences that can lead to aging and cancer. The study's findings hold promise for developing new dia...
The new model simplifies trial openings and streamlines patient enrollment, enabling rapid expansion across multiple locations. City of Hope operates a single centralized hub with diverse research locations, reducing patient enrollment times and increasing access to leading-edge treatment options.
A City of Hope study found that childhood cancer survivors are at risk for serious health issues, including new cancers and chronic conditions like heart disease. Early screening is crucial to prevent these conditions, which can be managed with treatment.
City of Hope launches Phase 2 trial to test nonsurgical treatment strategy for rectal cancer, and a Phase 1 trial explores novel drug triapine for glioblastoma. A liquid biopsy shows promise for early detection of gastric cancer with high accuracy.
City of Hope research demonstrates a new drug combination that slows advanced prostate cancer growth without improving overall survival. A novel AI conversation tool helps scientists uncover gene-disease connections without programming expertise.
The Stephenson Global Scholar Grants Program awards $5.3 million to six researchers tackling urgent challenges in pancreatic cancer, from early detection to immunotherapy and precision medicine.
Researchers found that belly fat increases in middle age due to active adipose progenitor cells, a new type of cell linked to fat creation. CD84 is validated as a potential target for AML, while subtle workplace challenges to women's authority accumulate over time, leading to increased burnout.
Dr. Fong showcases advancements in liver surgery, gene therapy, and remote surgery, aiming to make exceptional cancer surgery accessible to everyone worldwide. He also highlights the potential of AI and wearables to improve patient outcomes and enhance surgical precision.
City of Hope has launched a novel generative AI platform called HopeLLM, which leverages multiple commercial and open-source AI models. The platform enables doctors to spend more time interacting with patients, reducing the administrative burden of new patient onboarding and providing personalized treatment options.
Researchers discovered that a protein called BNIP3 plays a critical role in preserving mitochondrial health and reducing immune responses in type 1 diabetes. Boosting BNIP3 activity may help preserve beta cell function and prevent cellular destruction.
Researchers at City of Hope have made significant progress in understanding the role of paxillin in cellular signaling networks, providing new insights into potential cancer treatments. The study reveals that disrupting the interaction between paxillin and focal adhesion proteins could be a viable target for therapy.
Researchers from City of Hope will present novel cancer treatment approaches and combinations, including innovative combination therapies for breast, genitourinary, and gastrointestinal cancers. Additionally, they'll discuss the safety of readministering trastuzumab-deruxtecan to metastatic breast cancer patients with low-grade lung co...
The article showcases groundbreaking research advancements in cancer, diabetes, and type 1 diabetes. Researchers at City of Hope highlight the importance of maintaining a healthy weight to prevent MGUS from developing into myeloma.
City of Hope's largest outpatient facility, Hope Plaza, brings together cancer experts for highly individualized care. The center offers cutting-edge technologies, over 735 clinical trials, and integrated supportive services.
City of Hope experts will present new cancer treatment approaches, targeted therapies and lifestyle changes aimed at reducing cancer risk and improving survival. Highlights include discussions on biomarkers in kidney cancer, symptom science and palliative care.
Researchers with City of Hope will present innovative clinical trial results, breakthrough diagnostic techniques, and advances in treatment options at the AACR Annual Meeting. Highlights include a phase 3 clinical trial showing promising results for novel immunotherapy against nasopharyngeal carcinoma.
Researchers at City of Hope discovered a novel target for preventing age-related abdominal fat by identifying the cellular culprit behind midsection widening in middle age. The study found that aging triggers the arrival of new adult stem cells and enhances the body's massive production of new fat cells, especially around the belly.
A Phase 3 clinical trial has shown that a combination of sotorasib and panitumumab significantly improves progression-free survival in patients with KRAS G12C metastatic colorectal cancer. The study found improved overall survival rates, with the high-dose sotorasib group experiencing a 30% prolongation compared to standard care.
Researchers with City of Hope will present more than 74 sessions on emerging technologies in cancer research, advances in natural killer cells, new clinical trial results, and precision medicine. The presentations will explore the use of artificial intelligence and multiomics to improve cancer care.
Scientists at City of Hope have identified a new molecular target for treating pancreatic cancer, using an experimental drug to slow tumor growth and damage tumor cells. The approach showed promise in clinical trials with two patients, resulting in up to a 49% shrinkage in liver metastases.
A new tool called InflaMix uses machine learning to assess a patient's likely response to CAR T cell therapy by testing for inflammation biomarkers. The model was found to be associated with a high risk of treatment failure, including increased risk of death or disease relapse.
Researchers at City of Hope discovered that mutated cells can persist for years without becoming cancer and require an additional inflammatory push for malignancy to occur. Chronic inflammation is a key trigger for tumor formation, making it essential to avoid situations like high-fat diets and obesity.
Researchers aim to transform rectal cancer into a disease treatable with radiation therapy, avoiding long-term surgery side effects. Papaverine is investigated as a sensitizer that boosts oxygen content in tumor cells, allowing for maximal tumor destruction.
A phase 1/2 clinical trial is exploring whether denosumab, an osteoporosis medication, can protect and regenerate beta cells in people with early type 1 diabetes. The study aims to improve blood sugar control by preserving beta cell function.
A phase 1 clinical trial led by City of Hope demonstrated the safety and early efficacy of targeted chemotherapy using PIPAC combined with systemic chemotherapy for patients with colorectal and appendiceal cancer that has spread to the peritoneum of the abdominal cavity. The study showed promising results, including histologic, laparos...
Researchers at City of Hope have discovered a common drug that enhances the power of viral immunotherapy against multiple myeloma. In addition, studies suggest that circulating tumor DNA testing may not provide significant benefits for certain colorectal cancer patients. Remote patient monitoring after surgery shows promise in improvin...
Researchers discovered a specific type of regulatory T cell that can repair damaged thymus tissue. The discovery outlines a novel pathway to regeneration in the gland, offering a new approach to addressing thymic fatigue and damage.
City of Hope researchers and collaborators have developed a new method to facilitate encoding numerous features in T cells, allowing for the simultaneous targeting of multiple tumor escape mechanisms. The 'zip-sorting' system doubles genetic information capacity, enabling improved anti-tumor activity and longer-lived T cells.
Researchers at City of Hope have developed a blood test to identify patients with precancerous esophageal disease, offering promise for improved early screening. Additionally, the study discovered a mechanism linking aging and cellular dysfunction in breast cancer, suggesting potential biomarkers for early detection.
Researchers identified YTHDF2 as a key player in advancing blood cancers, which can help cancer cells evade immune system detection. A new compound CCI-38 targets and suppresses YTHDF2, reducing aggressive blood cancer growth.